Document text
Principal Investigator: Luigi Notarangelo
Organization: NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES
Fiscal Year: 2021
Award: $1,953,817
Funding agency: National Institute of Allergy and Infectious Diseases
In FY2021, we have identified a new gene defect responsible for an X-linked combined immunodeficiency and contributed to the characterization of three other forms of inborn errors of immunity (IEI), two of which are due to newly identified gene defects. We have also expanded knowledge on the molecular and cellular bases and clinical features of known forms of IE. Furthermore, we have reported on the experience with newborn screening for severe combined imune deficiency (SCID) and illustrated some of the challenges associated with it. We have also participated at multi-center retrospective studies aimed at defining current outcome of hematopoietic stem cell transplantation (HSCT) in selected forms of IEI, demonstrating significant progress in the treatment of these disorders. We have provided pre-clinical evidence in vitro that gene editing may correct the cellular phenotype of one of the most severe forms of IEI, SCID due to RAG2 deficiency. Finally, we have reported on clinical outcome and development of adaptive immune responses after SARS-CoV-2 infection in some forms of IEI.
In particular, the main results of the studies performed have been the following:
1) we have discovered a new X-linked combined immune deficiency due to mutations of the SASH3 gene, that encodes for an adaptor molecule. We have reported that this disease is characterized by susceptibility to severe and recurrent infections and treatment-refractory autoimmune cytopenias, associated with profound lymphopenia and neutropenia. Laboratory studies have shown that SASH3 plays a critical role in T-cell activation in response to TCR/CD3 engagement, and that SASH3 mutations are associated with increased apoptosis. These abnormalities have been reversed in vitro upon transfer of a normal copy of the SASH3 cDNA (publication #1).
2) By performing high-throughput sequencing of the TCR repertoire, we have contributed to define the cellular and molecular bases of two other novel forms of IEI, namely CD28 deficiency (publication #2) and PD-1 deficiency (publication #3). In particular, we demonstrated that TCR repertoire of these patients displayed normal diversity; this was also true for somatic revertants that were identified in patients with CD28 deficiency. These data have important implications on the mechanisms of intrathymic positive and negative selection of T cells, as they demonstrate that neither CD28 nor PD-1 play a critical role in these processes. We have
3) We also contributed to the characterization of the cellular and molecular phenotype of a patient with recalcitrant warts and rapidly progressing respiratory failure, due to mutation at the translation initiation site of the CD4 gene, leading to complete lack of CD4 surface expression (publication #4). Of note, we found that CD8+ T cells from this patient included MHC class II-restricted CMV-specific T cells, indicating tat compensatory mechanisms exist during thymic selection to endow CD8+ T cells with the capacity to recognize also MHC class II restricted antigens.
4) By performing in vitro T cell differentiation studies in a family with DNA polymerase delta 1 (POLD1) deficiency, we have demonstrated that this molecule plays acritical relent only in DNA repair but also in T cell development (publication #5)
5) By generating induced pluripotent stem cells from patients with TLR3 deficiency, followed by their targeted differentiation in vitro into cortical neurons, we have helped demonstrate that constitutive tonic TLR3 signaling inducing baseline type I IFN production controls antiviral immunity in central nervous system cells, and that defects of this pathway therefore lead to increased risk of herpes simplex encephalitis (publication #6).
6) We have conducted a series of studies that highlight the clinical, cellular and molecular heterogeneity of severe forms of IEI. These include the demonstration of bi-allelic ZAP70 mutations that lead to a SCID phenotype and yet retain the capacity of T cells to respond to mitogenic stimulation (publication #7), identification of an aberrant pattern of TCR alpha gene rearrangements in patients with TCR alpha constant chain (TRAC) gene deficiency (publication #8), and a series of publications illustrating the heterogeneity of clinical and laboratory features associated with RAG deficiency (publications #9-12).Besides generation of a reduced number of T cells (as observed in patients with hypomorphic RAG mutations), also partial impairment of signaling through the TCR/CD3 complex is a cause of autoimmunity, as demonstrated in patients with CD3 gamma (CD3G) deficiency (publication #13).
7) Autoimmunity is also a cardinal feature of Autoimmune Polyendocrinopathy Enteropathy Candidiasis Ectodermal Dystrophy (APECED), a condition characterized by high titers of autoantibodies targeting Inteferon-alpha (IFN_a) and IFN-omega (IFN-w). Consistent with the fact that these autoantibodies are associated with severe clinical curse in patients with COVID-19, we found that APECED patients are at high risk of poor outcome after SARS-CoV-2 infection (publication #14). Furthermore, we collaborated with the Lionakis Lab at NIAID to establish that increased IFN-gamma responses in patients and in a mouse model of APECED are a cause of chronic mucocutaneous candidiasis in this disease (publication #15). Nuclear factor kappa B2 (NFKB2) deficiency is another IEI with increased risk of autoimmunity. By studying the TCR repertoire of these patients, we have identified molecular signatures indicative of a self-reactive repertoire (publication #16). Finally, we explored other manifestations of immune dysregulation in IEI, including cerebellar ataxia and liver failure in patients with IPEX syndrome (publication #17) and nodular regenerative hyperplasia of the liver in patients with X-linked agammaglobulinemia (publication #18). T lymphocyte senescence is another mechanism contributing to imune dysregulation and impaired immunological surveillance against infections. By studying patients with CD40 ligand (CD40LG) deficiency, we have demonstrated that the CD8+ T cell compartment of these patients has signatures of cell senescence, which may contribute to the increased risk of infections in this disease (publication #19).
7) An important focus of our lab is the characterization of the cellular composition of the thymus in health and disease. We have used a mouse model of MHC-II deficiency to demonstrate that lack of MHC-II expression leads to perturbation of central and peripheral immunological tolerance (publication #20). In another study, we have defined that progressive T cell differentiation in the thymus is associated with finely regulated expression of phosphate transporters, uncovering a novel mechanism that regulates thymopoiesis (publication #21).
8) Since 2018, universal newborn screening for SCID is available across the country. We have reviewed the experience with this program, including its success and challenges (publications #22-24).
9) HSCT represents the mainstay of treatment for many IEI. We have reported on the success of HSCT for POMP deficiency (publication #25) and reviewed progress with HSCT for chronic granulomatous diseases and APDS (publications #26-27).
10) By performing gene editing in RAG2-mutated iPSCs, followed by targeted differentiation into T cells in vitro, we have produced proof of principle that gene editing can correct the cellular phenotype of the disease (publication #28). Similar results have bene obtained in MAGT1 deficiency (publication #29).
11) We have demonstrated that most patients with antibody deficiency retain the capacity to mount T- and B-cell responses to SARS-CoV2 (publication #30).
12) Finally, we have published several reviews on various aspects of IEI (publications #31-35).
Terms: <2019 novel corona virus><2019 novel coronavirus><2019-nCoV><70 kDa zeta-associated protein><Accounting><Affect><Alleles><Allelomorphs><Animal Model><Animal Models and Related Studies><Antibodies><Antigens><Apoptosis><Apoptosis Pathway><Autoantibodies><Autoimmune><Autoimmune Polyendocrinopathies><Autoimmune Status><Autoimmunity><B blood cells><B cell><B cell receptor><B cells><B-Cell Antigen Receptor><B-Cells><B-Lymphocytes><B-cell><Bruton agammaglobulinemia><Bruton's Sex-Linked Agammaglobulinemia><Bruton's X-Linked Agammaglobulinemia><CD154 Antigens><CD28><CD28 gene><CD3><CD3 Antigens><CD3 Complex><CD3 molecule><CD4 Antigen (P55) Gene><CD4 gene><CD40 Ligand><CD40-L><CD8 Cell><CD8 T cells><CD8 lymphocyte><CD8+ T cell><CD8+ T-Lymphocyte><CD8-Positive Lymphocytes><CD8-Positive T-Lymphocytes><CMV><CNS Nervous System><COVID infected patient><COVID patient><COVID positive patient><COVID-19><COVID-19 infected patient><COVID-19 infection><COVID-19 patient><COVID-19 positive patient><COVID-19 virus><COVID19><COVID19 infection><COVID19 patient><COVID19 positive patient><COVID19 virus><CV-19><CV19><Candidiasis><Candidosis><Cell Aging><Cell Body><Cell Communication and Signaling><Cell Compartmentation><Cell Compartmentations><Cell Senescence><Cell Signaling><Cells><Cellular Aging><Cellular Senescence><Central Nervous System><Cerebellar Ataxia><Cerebellar Incoordination><Chronic Granulomatous Disease><Chronic Mucocutaneous Candidiasis><Class II Genes><Clinical><CoV-2><CoV2><Complementary DNA><Country><Cytomegalovirus><DNA Damage Repair><DNA Polymerase III><DNA Polymerase delta><DNA Rearrangement><DNA Repair><DNA Therapy><DNA-Dependent DNA Polymerase III><Data><Defect><Development><Disease><Disorder><Family><Gamma interferon><Gene Rearrangement><Gene Transfer Clinical><Generations><Genes><Genetic Alteration><Genetic Change><Genetic Diseases><Genetic Intervention><Genetic defect><HCMV><HIGM1><HLA Class II Genes><HSC transplantation><Health><Hematopoietic Stem Cell Transplant><Hematopoietic Stem Cell Transplantation><Hepatic Failure><Hereditary Disease><Herpes Simplex Encephalitis><Herpes encephalitis><Herpetic Encephalitis><Heterogeneity><High-Throughput Nucleotide Sequencing><High-Throughput Sequencing><Human><IFN><IFN-Gamma><IFN-g><IFN-γ><IFNG><IFNγ><IMD3><Immune><Immune Interferon><Immune Surveillance><Immune Tolerance><Immune system><Immunes><Immunity><Immunodeficiency Disorder><Immunodeficiency Syndrome><Immunologic Deficiency Syndromes><Immunologic Surveillance><Immunologic Surveillances><Immunologic Tolerance><Immunological Deficiency Syndromes><Immunological Surveillance><Immunological Surveillances><Immunosurveillance><Impairment><In Vitro><Inborn Genetic Diseases><Infection><Inflammatory><Inherited disorder><Innate Immunity><Inorganic Phosphate Transporter><Interferon Gamma><Interferon Type II><Interferon-gamma><Interferons><Intracellular Communication and Signaling><Knowledge><Laboratories><Laboratory Study><Lead><Link><Liver Failure><Lymphocytopenia><Lymphopenia><MHC Class II><MHC Class II Genes><Modern Man><Molecular><Molecular Fingerprinting><Molecular Profiling><Moniliasis><Multi-center studies><Multicenter Studies><Mutate><Mutation><NIAID><National Institute of Allergy and Infectious Disease><Native Immunity><Natural History><Natural Immunity><Nature><Neonatal Screening><Nerve Cells><Nerve Unit><Neural Cell><Neuraxis><Neurocyte><Neurons><Neutropenia><Newborn Infant Screening><Non-Specific Immunity><Nonspecific Immunity><Nuclear><OKT3 antigen><Outcome><PD 1><PD-1><PD1><Pathway interactions><Patients><Pattern><Pb element><Peripheral><Phenotype><Phosphate Transport Proteins><Phosphate Transporters><Play><Pol III><Predisposition><Process><Production><Programmed Cell Death><Protein Tyrosine Kinase Zap70><Publications><Publishing><R-Series Research Projects><R01 Mechanism><R01 Program><Receptor-CD3 Complex, Antigen, T-Cell><Refractory><Replicative Senescence><Reporting><Research Grants><Research Project Grants><Research Projects><Respiratory Failure><Retrospective Studies><Risk><Role><SARS corona virus 2><SARS-CoV-2><SARS-CoV-2 infected patient><SARS-CoV-2 infection><SARS-CoV-2 patient><SARS-CoV-2 positive patient><SARS-CoV2><SARS-CoV2 infection><SARS-associated corona virus 2><SARS-associated coronavirus 2><SARS-coronavirus-2><SARS-related corona virus 2><SARS-related coronavirus 2><SARSCoV2><SRK><Salivary Gland Viruses><Scientific Publication><Series><Severe Acute Respiratory Distress Syndrome CoV 2><Severe Acute Respiratory Distress Syndrome Corona Virus 2><Severe Acute Respiratory Distress Syndrome Coronavirus 2><Severe Acute Respiratory Syndrome CoV 2><Severe Acute Respiratory Syndrome-associated coronavirus 2><Severe Acute Respiratory Syndrome-related coronavirus 2><Severe acute respiratory syndrome associated corona virus 2><Severe acute respiratory syndrome corona virus 2><Severe acute respiratory syndrome coronavirus 2><Severe acute respiratory syndrome coronavirus 2 infection><Severe acute respiratory syndrome related corona virus 2><Signal Transduction><Signal Transduction Systems><Signaling><Site><Surface><Susceptibility><Syk-related tyrosine kinase><Syndrome><T cell differentiation><T cell receptor repertoire sequencing><T cell receptor sequencing><T-B Cell Activating Molecule><T-Cell Activation><T-Cell Antigen T4/LEU3 Gene><T-Cell Development><T-Cell Ontogeny><T-Cell Receptor Alpha Locus><T-Cell Receptor alpha Genes><T-Cell Receptor alpha-Chain Genes><T-Cell gp39 Antigen><T-Cells><T-Lymphocyte><T-Lymphocyte Development><T-cell receptor repertoire><T-cell surface antigen T4/Leu-3 Gene><T3 Antigens><T3 Complex><T3 molecule><T44><T8 Cells><T8 Lymphocytes><TCR repertoire><TCR repertoire sequencing><TCR sequencing><TCR-CD3 Complex><TCR-seq><TCRA><TCRseq><TLR3><TLR3 gene><TNF-Related Activation Protein><TRA@ gene cluster><TcR alpha Genes><Thymus><Thymus Gland><Thymus Proper><Thymus Reticuloendothelial System><Toll-Like Receptor 3><Translation Initiation><Tumor Necrosis Factor Ligand Superfamily Member 5><Unscheduled DNA Synthesis><Wuhan coronavirus><X-Linked Agammaglobulinemia><ZAP-70><ZAP-70 Gene><ZAP-70 Kinase><ZAP-70 protein><ZAP70><Zeta-Chain Associated Protein Kinase><adaptive immune response><adaptive immunity><allergic/immunologic body system><allergic/immunologic organ system><anti-viral immunity><antiviral immunity><autoimmune antibody><autoreactive antibody><base><biological signal transduction><cDNA><clinical heterogeneity><clinical outcome prediction><corona virus disease 2019><coronavirus disease 2019><coronavirus disease 2019 infected patient><coronavirus disease 2019 infection><coronavirus disease 2019 patient><coronavirus disease 2019 positive patient><coronavirus disease 2019 virus><coronavirus disease infected patient><coronavirus disease patient><coronavirus disease positive patient><coronavirus patient><cytomegalovirus group><cytopenia><developmental><disease phenotype><experience><gene therapy><gene-based therapy><genetic condition><genetic disorder><genetic therapy><genome mutation><genomic therapy><hCoV19><heavy metal Pb><heavy metal lead><hematopoietic cell transplantation><hereditary disorder><heritable disorder><high risk><human model><hypoimmunity><iPS><iPSC><iPSCs><immune deficiency disorder><immune system tolerance><immune unresponsiveness><immunodeficiency><immunogen><immunological paralysis><in vivo><inborn error><induced pluripotent stem cell><infected with COVID-19><infected with COVID19><infected with SARS-CoV-2><infected with SARS-CoV2><infected with coronavirus disease 2019><infected with severe acute respiratory syndrome coronavirus 2><infection recurrence><infection risk><inherited diseases><inherited genetic disease><inherited genetic disorder><lFN-Gamma><liver hyperplasia><lung failure><model of animal><model of human><model organism><molecular phenotype><molecular profile><molecular signature><mouse model><murine model><nCoV2><neuronal><new therapeutic approach><new therapeutic intervention><new therapeutic strategies><new therapy approaches><newborn screening><novel><novel therapeutic approach><novel therapeutic intervention><novel therapeutic strategies><novel therapy approach><pathogen><pathway><patient infected with COVID><patient infected with COVID-19><patient infected with SARS-CoV-2><patient infected with coronavirus disease><patient infected with coronavirus disease 2019><patient infected with severe acute respiratory syndrome coronavirus 2><patient with COVID><patient with COVID-19><patient with COVID19><patient with SARS-CoV-2><patient with coronavirus disease><patient with coronavirus disease 2019><patient with severe acute respiratory distress syndrome coronavirus 2><pre-clinical><preclinical><predict clinical outcome><predictor of clinical outcome><programmed cell death 1><programmed cell death protein 1><programmed death 1><programs><pulmonary failure><recurrent infection><regenerative><response><self reactive antibody><senescence><senescent><severe acute respiratory syndrome coronavirus 2 infected patient><severe acute respiratory syndrome coronavirus 2 patient><severe acute respiratory syndrome coronavirus 2 positive patient><sle2><social role><success><systemic lupus erythematosus susceptibility 2><thymus derived lymphocyte><tool>